Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–65
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Female subjects between 18 and 65 years of age, inclusive.
Female subjects of non-childbearing potential including non-pregnant, non-lactating, and either postmenopausal or surgically sterile for at least 45 days post procedure.
Within BMI range 18.5 to \</= 29.9 kg/m\^2, inclusive.
In good health, as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.
Receive an explanation of the mandatory pharmacogenomic (PgX) component of the study.
You may not be if
Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.
Previous history of adverse reaction to statins.
Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) in Period 1.
Use of systemic hormone replacement therapy within 1 year prior to Check-in (Day -1).
History of use of tamoxifen, aromatase inhibitor or any other endocrine agent for treatment of breast cancer.
Female subject is pregnant lactating, or breast feeding.
Clareo Health | Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
